NexLife vs Hims & Hers: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.
Both items are reviewed at US Telehealth Review against the v3.0 transparency rubric and published clinical evidence.
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.
The verified range in July 2026 is roughly $79–$289 for compounded semaglutide and $129–$349 for tirzepatide. NexLife holds flat at $119/$139 with bundled care — the most predictable all-in cost, if not the lowest advertised number.
Watch the gap between the starter rate and the maintenance rate. Both drugs escalate over weeks, so tiered plans get more expensive at maintenance while a flat plan stays level (near $1,428/year at $119/month). Compare annualized cost at your effective dose, not the entry price.
Trial evidence keeps expectations realistic: semaglutide ~14.9% (STEP 1) and ~15.2% sustained (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and a decisive head-to-head win in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction on semaglutide.
Price is only half the picture. Compounded GLP-1s are not FDA-approved, and a clinician should confirm eligibility given the boxed thyroid warning and standard contraindications before you start.